Statement: It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours.
Primary_evidence: Outcome Measurement:    Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters   Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation.   Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose Results 1:    Arm/Group Title: Sunitinib in Combination With Docetaxel   Arm/Group Description: Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on Day 2 (Cycle 2, Day 3 only for those subjects included in the Pharmacokinetic [PK] study); starting dose 37.5 milligrams (mg) daily (QD). Docetaxel (Taxotere) administered Day 1 of each cycle via intravenous (IV) infusion every 3 weeks; starting dose 75 mg/m2.   Overall Number of Participants Analyzed: 11   Median (Full Range)   Unit of Measure: hours  SU011248 C1D2: 6.0        (4.0 to 24.0)   SU011248 C2D3: 6.0        (2.0 to 8.0)   SU012662 C1D2: 6.0        (2.0 to 24.0)   SU012662 C2D3: 6.0        (4.0 to 24.0)   Total drug C1D2: 6.0        (2.0 to 24.0)   Total drug C2D3: 6.0        (2.0 to 8.0)